News

Clinical Trial Design Series: Consumer Involvement in Grants

Consumer involvement can strengthen research design and grant applications. This practical guide explains when to involve consumers, what to ask, how to document their influence and how to plan ongoing involvement.

What is Consumer Involvement in Research?

Consumer involvement means research being conducted with input from people with lived experience, rather than consumers only participating as research subjects. In grant development, consumers may help identify research priorities, review study design and participant burden, consider patient-important outcomes and recruitment barriers, and contribute to decisions about how research is conducted and communicated.

Consumer and community involvement is increasingly prominent in health and medical research funding. But a strong grant application needs to demonstrate more than the fact that consumers were consulted. 

Reviewers should be able to see what consumers contributed, whether their input influenced the proposed research, how they will continue to contribute during the study, and how their involvement is appropriately supported. 

Getting Started with Consumer Involvement in Research Grants 

Chances are you’ve already met consumers, or undertaken consumer engagement, but how do you demonstrate consumer involvement in grant writing? 

TOGA has developed a TOGA Consumer Review and Grant Planning Tool to help researchers involve consumers while a study is still being developed and then translate that involvement into evidence for the grant application. The tool prompts researchers to explain their proposed study to consumers, ask focused questions, record what consumer input confirmed or changed, and identify where this evidence should appear in the grant. 

To see how the tool can work, review the completed form for a fictional study. 

Additionally, you can access free training on consumer and community involvement (CCI) in grant writing. 

timeline and process of submitting a research grant
Timeline showing opportunities for consumer involvement from research concept submission through TOGA review to grant submission.

When Should Consumers be Involved in a Research Grant?  

Start early, while the research can still change. Consumer involvement is most useful when it begins before the research design and grant application are finalised.  This provides an early opportunity to consider the proposed research from a lived-experience perspective. 

Where a grant would benefit from more detailed discussion, investigators can also request a separate review with a broader group of TOGA consumers. This allows more time to explore issues such as study burden, endpoints, recruitment and access before the grant is submitted. 

The objective is not to add consumer review as the final step before submission. It is to create enough time for researchers to consider and respond to the input they receive. 

More involvement is not necessarily better. The goal is purposeful consumer involvement where lived experience can inform the research, with clear evidence of what consumers contributed and influenced.

Consumer Involvement in Research Priority Setting 

Consumer involvement does not necessarily begin with an individual grant.  Consumers may also contribute to research priority setting, including through forums where researchers and consumers consider unmet needs and potential research questions together. If a proposal subsequently addresses a priority identified through one of these processes, this is relevant evidence for a grant application. 

The application can describe the sequence: 

Consumer Priority Setting
Research Concept to Address Need
Project-Specific Consumer Review
Research Decisions

Researchers do not need to ask a new group of consumers to rediscover the same unmet need simply to demonstrate involvement. Instead, the application should explain how previous priority-setting informed the research and then show how consumers contributed to the development of the specific proposal. 

How to Involve Consumers in Research Design 

Asking consumers “What do you think of our study?” is unlikely to produce the most useful input. Consumers can contribute most effectively when researchers explain the proposed study in accessible language and ask focused questions about areas where lived experience provides expertise. 

The TOGA tool structures review around six areas.

1. Research question and potential benefit

Explain the research question, the unmet need and what the study is intended to achieve. 

Ask: Does the study address an important problem or unmet need for people affected by lung cancer? Is the potential benefit meaningful? 

This can either identify a problem with the proposed research or provide evidence that consumers consider the research relevant and worthwhile.

2. Primary and secondary outcomes

Explain the primary endpoint in plain language and describe the major secondary outcomes. 

Consumers can then consider whether the primary outcome is important to patients, whether the relative priority given to different outcomes is appropriate, and whether important outcomes are missing. These might include symptoms, quality of life, toxicity, function, treatment burden, time spent receiving healthcare or effects on everyday life. 

Consumers do not need to select the statistical endpoint or design the analysis. Their contribution is to test whether what researchers propose to measure adequately captures outcomes that are important to patients.

3. Would patients participate?

Explain what participation actually involves, including the intervention, randomisation, potential risks and additional study requirements. 

Ask whether people would consider participating and what might encourage or discourage them. 

Consumers may identify aspects of randomisation, testing or treatment that are difficult to understand or could make people reluctant to participate.

4. Participant burden

Consumers should be able to see what participation requires beyond usual care. Where available, providing the Schedule of Assessments can be particularly useful. 

Ask about additional visits, blood tests, scans, biopsies, questionnaires, treatment, travel, time away from work or family and out-of-pocket costs. This can identify opportunities to reduce burden before the protocol is finalised.

5. Access and inclusion

Explain who can participate, where the study will run and the important eligibility requirements. 

Consumers can help identify whether the proposed design could unintentionally make participation harder for particular groups because of geography, age, disability, language or cultural needs, financial burden or access to trial sites.

6. Ask what you have missed

Finally, give consumers an opportunity to consider the study as a whole. There may be an issue that does not fit neatly into the questions researchers thought to ask. 

The form will also prompt you to record what happened to the feedback. Consumer involvement does not mean every consumer recommendation must be adopted. The important step is demonstrating that the input was genuinely considered. 

The TOGA tool therefore asks researchers to record each outcome as: 

Confirmed as proposed | Modified following consumer input | Consumer recommendation not adopted 

It then asks researchers to document: 

Consumer Input
Research Decision
Consequence

This distinction is useful when writing the grant. 

If consumers recommend a change and it is adopted, describe the change: Consumers identified treatment-related travel as a potential barrier to participation. In response, telehealth follow-up was incorporated where clinically appropriate. 

But confirmation can also demonstrate involvement: Consumers reviewed the proposed primary endpoint and considered it meaningful to patients. No change was recommended. 

A research team should also be able to document why a recommendation was not adopted. That does not necessarily need valuable space in the grant application unless it is particularly relevant. The project record can retain that information while the grant focuses on the strongest evidence of consumer contribution. 

How do you Demonstrate Consumer Involvement in a Grant Application?  

Once the review is complete, do not confine everything that happened to the dedicated consumer involvement section. The application should tell a consistent story. 

The TOGA tool asks researchers to identify where each piece of consumer input belongs, including the plain-language summary, significance and rationale, study design, endpoints, feasibility, recruitment and retention, diversity and equity, impact and translation, as well as the dedicated consumer involvement section. 

For example, if consumers influenced an endpoint, that should be visible where the endpoints are described. If they identified a recruitment barrier that changed the study design, the resulting strategy should appear in the recruitment or feasibility section. 

The dedicated consumer involvement section can then bring those contributions together rather than introducing them for the first time. 

How to Involve Consumers Throughout a Research Study 

A strong application should also distinguish involvement that has already occurred from involvement proposed if the grant is funded. The appropriate role will vary between studies. 

For a clinical trial, ongoing involvement might include review of participant-facing materials and the Participant Information and Consent Form, review of the Schedule of Assessments where relevant, advice when recruitment or retention problems emerge, and involvement in interpreting or communicating findings. 

Consumers may also have representation on a Trial Steering or Oversight Committee, providing strategic input and contributing to decisions at key points during the study. This does not mean consumers need to participate in every operational or highly technical aspect of trial management. Their role should be defined around decisions and activities where lived experience can make a useful contribution. 

The grant should therefore be specific. Rather than promising “ongoing consumer involvement throughout the project”, describe the role, when it occurs and what consumers will be able to influence. 

How to Support and Resource Consumer Involvement in Research 

Consumers should not be expected to arrive with expertise in clinical trial methodology. Researchers need to provide enough context for them to contribute their own expertise effectively. 

The TOGA tool prompts researchers to consider clear roles and expectations, governance arrangements, remuneration, orientation or training, accessible information, administrative and meeting support, participation costs and an adequate allocation within the grant budget. 

Additionally, remuneration should be planned from the beginning and supported by the appropriate guideline-specified rate rather than added to the budget at the end. 

How to Involve Consumers in Research Dissemination and Translation 

Consumer involvement should not finish when recruitment closes. Consumers can help researchers consider how findings should be communicated to participants and the broader community, review plain-language results summaries, contribute to dissemination through consumer networks, and provide perspectives on translation of findings into practice. 

The grant should therefore answer two related questions: what benefit could this research produce for consumers and communities, and how will those communities hear about the results? 

This is also an opportunity to demonstrate consideration of populations who may experience different access, disease burden or outcomes rather than treating “the consumer” as a single homogeneous perspective. 

Grant Checklist 

Before submitting, researchers should be able to demonstrate four things: 

  1. What happened before submission? Who was involved, what they contributed, and what changed or was confirmed
  2. What will happen during research? Defined ongoing roles and areas of consumer influence
  3. How will involvement be supported? Governance, role clarity, remuneration, orientation and practical resources
  4. How will consumers and communities benefit? Relevance, patient-important outcomes, diversity and access, expected impact and return of findings to the community

The objective is not the greatest possible level of consumer involvement in every research activity. It is involvement that is purposeful, credible and appropriate to the research. A useful final test is the one built into the TOGA tool: 

Consumer Input: Reviewer can follow connection
Research Decision
Consequence: Evidence shown in relevant parts of grant

If they can, consumer involvement has become part of the research story rather than an additional section written shortly before submission. 

Summary: Five Tips for Consumer Involvement in a Strong Grant Application 

  1. Start early. Involve consumers while the research design can still change.  
  2. Ask focused questions. Seek input on the research need, patient-important outcomes, participation, burden and access.  
  3. Record the result. Capture what consumer input confirmed or changed.  
  4. Show the influence throughout the grant. Don’t confine consumer involvement to the CCI section.  
  5. Plan ongoing involvement. Define what consumers will contribute during the research, how they will be supported and how findings will return to communities.  

Use the TOGA Consumer Review and Grant Planning Tool to structure your consumer review and turn the feedback into grant-ready evidence. Lean into the existing TOGA review pathway for endorsement to seek your consumer involvement. 

Useful resources:  

Share this

Facebook
Twitter
LinkedIn
Learn how tarlatamab targets DLL3, the evidence from the DeLLphi clinical trials, and the current Australian access pathway for relapsed small cell lung cancer.
Learn how antibody-drug conjugates (ADCs) work in lung cancer, the major clinical trials, emerging biomarkers and how these targeted therapies are changing treatment.
Occasionally, there will be one presentation that stands out for a different reason. See why Dr Prem Ram's talk changed the game.
Learn what a KRAS G12C mutation means, how targeted therapies work, and how Australian clinical trials are testing new lung cancer treatments.
The PHARAOH-A trial will evaluate savolitinib plus osimertinib in MET-positive amplified or overexpressed EGFR-mutated lung cancer after progression on prior TKI and chemotherapy.
New evidence is changing the way surgeons approach early-stage lung cancer, with lung-sparing surgery becoming an option for carefully selected patients.
Everything you need to know about the Australia-wide trial using liquid biopsy to guide treatment after targeted therapy progression in advanced lung cancer
The DEFIANT trial will evaluate datopotamab deruxtecan (Dato-DXd) in EGFR exon 20 insertion NSCLC after targeted therapy and chemotherapy.
Discover the major advances from TOGA ASM 2026, including lung cancer screening, precision medicine, immunotherapy, survivorship and multidisciplinary care shaping the future of thoracic oncology.
Professor Robert Stirling OAM devoted his career to improving the lives of people with lung cancer through clinical excellence, research, education and compassionate leadership.
Their work is often invisible, but its impact isn't. Specialist Lung Cancer Nurses are quietly becoming the backbone of modern lung cancer care.
Teletrials, also known as digi trials, are when a clinician at a primary site uses telehealth (videoconference or telephone calls) to enrol, consent, treat and/or
A simple guide to what happens after a lung CT scan in the Australian National Lung Cancer Screening Program
Updates from our Inspirational Research Grant 2025 recipients on pioneering lung microbiome research and its impact on immunotherapy efficacy.
Clinicians, nurses, consumers and health service leaders came together at TOGA’s Lung Cancer Optimal Care Pathway workshop to examine why Australia continues to struggle to
Understanding the language helps patients, families and clinicians stay informed, confident and part of the conversation.
TOGA is pleased to announce the latest appoints for our Scientific Committee.
Discover how a vibrant Lunar New Year Banquet, organised by Dr. Angeline Low and Ms. Maria Chan, raised over $50,000 for vital lung cancer research.
The MRFF is holding $1B+ in unspent funds. Learn why TOGA is calling for the release of this research funding to accelerate lung cancer breakthroughs
Discover TOGA’s FY25 highlights, including the new Strategic Plan, clinical trial milestones and record membership growth across Australia and New Zealand.
The Preventative and Quality Care Working Group represents TOGA’s commitment to improving the outcomes of thoracic cancers.
TOGA’s Working Groups are evolving to better reflect where thoracic cancer research is heading: From prevention and early detection through to advanced disease and living
Learn how to turn your endorsed research concept into a clinical trial; from sponsor selection to budgeting, data, safety and protocol design.
Learn how to design an investigator-initiated clinical trial, from refining your research idea to securing TOGA endorsement and funding.
Learn why EGFR-positive lung cancer disproportionately affects Asian populations and non-smokers. Discover modern targeted therapies and symptoms to watch for.
Discover how 2025 transformed lung cancer care in Australia. Explore the impact of national screening, modern diagnostics, and new PBS treatment approvals.
Let's take a moment to celebrate the incredible guests, ground breaking discussions, and dedicated listeners that made 2025 our most successful year yet.
If you are interested in joining TOGA on a Committee, please submit your nominations by 30 January 2026
The final Scientific Meeting of 2025 was held in November. Five concepts were presented, spanning both Recurrent and Metastatic NSCLC populations and four Mesothelioma concepts.
Bispecific antibodies bind two different targets at once, reshaping lung cancer treatment through dual checkpoint blockade and targeted precision.
Research advances only improve outcomes when they are accessible to patients. TOGA drives change in lung cancer care by advocating through stakeholder submissions, including PBS.......
We are excited about awarding new grants but first, we check in on progress made by our 2024 recipients....
Learn how TOGA’s ASPiRATION study led to Medicare-funded genomic testing for lung cancer and national best practice guidelines in Australia.
Optimise cancer care for older Adults with practical tips and tools to implement person-centred geriatric oncology.
DYNAMALK is a significant clinical trial investigating the potential of comprehensive genomic profiling to revolutionise the treatment of ALK+ Non-Small Cell Lung Cancer (NSCLC)
Liquid biopsy is revolutionising lung cancer care by using a blood test to examine the tumour without the need for a lung biopsy.